Overview

Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers

Status:
NOT_YET_RECRUITING

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN5681 in Adult healthy subjects

Phase:

PHASE1

Details

Lead Sponsor:

Ikaria Bioscience Pty Ltd

Collaborator:

Shanghai Rona Therapeutics Co., Ltd.